https://wikimd.com/index.php?action=history&feed=atom&title=GiredestrantGiredestrant - Revision history2026-04-21T23:31:46ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.com/index.php?title=Giredestrant&diff=6427859&oldid=prevPrab: CSV import2025-03-05T06:15:27Z<p>CSV import</p>
<p><b>New page</b></p><div>{{Short description|Selective estrogen receptor degrader}}<br />
{{Drugbox<br />
| verifiedfields = changed<br />
| verifiedrevid = 477002123<br />
| image = [[File:Giredestrant.svg|Chemical structure of Giredestrant|thumb|right]]<br />
| IUPAC_name = (1S,2R)-2-(4-((1R,2R)-2-(4-cyanophenyl)cyclopropyl)phenoxy)-1-(3-hydroxypropyl)cyclopropan-1-ol<br />
| tradename =<br />
| synonyms = GDC-9545<br />
| CAS_number = 2411274-68-3<br />
| ATC_prefix =<br />
| ATC_suffix =<br />
| PubChem = 137460970<br />
| ChemSpiderID = 64835292<br />
| UNII =<br />
| KEGG =<br />
| ChEMBL = 4297640<br />
| C=22<br />
| H=23<br />
| N=1<br />
| O=3<br />
| smiles = C1C[C@@H]([C@@H]1C2=CC=C(C=C2)C3CC3C4=CC=C(C=C4)C#N)OCCCO<br />
}}<br />
<br />
'''Giredestrant''' is a [[selective estrogen receptor degrader]] (SERD) that is being investigated for the treatment of [[hormone receptor-positive breast cancer]]. It is designed to bind to the [[estrogen receptor]] and induce its degradation, thereby inhibiting the growth of estrogen-dependent tumors.<br />
<br />
==Mechanism of Action==<br />
Giredestrant functions by targeting the estrogen receptor (ER), a nuclear hormone receptor that is activated by the hormone [[estrogen]]. In hormone receptor-positive breast cancer, the growth of cancer cells is often driven by estrogen signaling through the ER. Giredestrant binds to the ER and promotes its degradation, reducing the receptor's ability to mediate estrogen signaling. This action helps to inhibit the proliferation of cancer cells that rely on estrogen for growth.<br />
<br />
==Clinical Development==<br />
Giredestrant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with hormone receptor-positive breast cancer. These trials aim to determine the optimal dosing regimen and to assess the drug's effectiveness in comparison to existing therapies such as [[tamoxifen]] and [[aromatase inhibitors]].<br />
<br />
==Pharmacokinetics==<br />
The pharmacokinetic profile of giredestrant includes its absorption, distribution, metabolism, and excretion. Giredestrant is administered orally, and its bioavailability is influenced by factors such as food intake and patient-specific variables. The drug is metabolized primarily in the liver, and its metabolites are excreted via the urine and feces.<br />
<br />
==Potential Benefits==<br />
Giredestrant offers potential benefits over traditional therapies by providing a novel mechanism of action that directly targets and degrades the estrogen receptor. This could lead to improved outcomes for patients with hormone receptor-positive breast cancer, particularly those who have developed resistance to other forms of endocrine therapy.<br />
<br />
==Side Effects==<br />
As with any therapeutic agent, giredestrant may cause side effects. Commonly reported side effects in clinical trials include [[nausea]], [[fatigue]], and [[hot flashes]]. The safety profile of giredestrant continues to be evaluated in ongoing studies.<br />
<br />
==Related Pages==<br />
* [[Breast cancer]]<br />
* [[Estrogen receptor]]<br />
* [[Selective estrogen receptor degrader]]<br />
* [[Endocrine therapy]]<br />
<br />
[[Category:Selective estrogen receptor degraders]]<br />
[[Category:Experimental cancer drugs]]</div>Prab